Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Pediatr Blood Cancer. 2011 Sep 9;58(3):362–365. doi: 10.1002/pbc.23317

Table II.

Non-neurologic adverse events that were possibly, probably or definitely attributed to IT topotecan in 20 eligible patients*

Event Grade
1 2 3 4
Fatigue 1 - - -

Fever 1 2 - -

Weight Loss - 1 - -

Injection Site Reaction - 1 1 -

Infection/Febrile Neutropenia - - 1 1

Pain 1 1 1 -

Dermatologic 1 - - -

Gastrointestinal 5 4 - 1

Hepatic 1 - 3 -

Metabolic 2 1 - -

Hematologic - 2 1 3
*

More than 1 event may have occurred in the same patient